Portal de Periódicos da CAPES

Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors

2010; Elsevier BV; Volume: 404; Issue: 1 Linguagem: Inglês

10.1016/j.bbrc.2010.11.064

1090-2104

Hui Song, Chia‐Wei Li, Adam M. LaBaff, Seung-Oe Lim, Long‐Yuan Li, Shu-Fen Kan, Yue Chen, Kai Zhang, Jing‐Yu Lang, Xiaoming Xie, Yan Wang, Long-Fei Huo, Sheng-Chieh Hsu, Xiaohong Chen, Yingming Zhao, Mien‐Chie Hung,

Peptidase Inhibition and Analysis

Alteration of epidermal growth factor receptor (EGFR) is involved in various human cancers and has been intensively investigated. A plethora of evidence demonstrates that posttranslational modifications of EGFR play a pivotal role in controlling its function and metabolism. Here, we show that EGFR can be acetylated by CREB binding protein (CBP) acetyltransferase. Interestingly, EGFR acetylation affects its tyrosine phosphorylation, which may contribute to cancer cell resistance to histone deacetylase inhibitors (HDACIs). Since there is an increasing interest in using HDACIs to treat various cancers in the clinic, our current study provides insights and rationale for selecting effective therapeutic regimen. Consistent with the previous reports, we also show that HDACI combined with EGFR inhibitors achieves better therapeutic outcomes and provides a molecular rationale for the enhanced effect of combination therapy. Our results unveil a critical role of EGFR acetylation that regulates EGFR function, which may have an important clinical implication.